It can be hard to keep track of new brain tumor clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.**
- ONC206 for newly diagnosed or recurrent diffuse midline gliomas and other recurrent malignant brain tumors (PNOC 023)
- This phase I trial studies the effects and best dose of the drug ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that are newly diagnosed or have come back (recurrent) or in other recurrent primary malignant brain tumors.
- A comprehensive evaluation of tumor oxygenation, metabolism, and blood supply of high-grade glioma using dynamic FAZA PET and multiparametric MR
- This is a pilot trial evaluating the use of several advanced medical imaging techniques to study high-grade glioma tumors.
- Multimodality MRI and liquid biopsy in GBM
- This is a non-therapeutic pilot trial that will evaluate imaging methods and liquid biopsy techniques to study glioblastoma.
- Simultaneous multinuclear metabolic MRI in newly diagnosed or recurrent glioma
-
- This clinical trial develops and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.
- Study of PBI-200 in subjects with NTRK fusion-positive solid tumors
- This is a first-in-human, phase I/II trial of the drug PBI-200 in subjects with NTRK fusion-positive advanced or metastatic solid tumors, including brain tumors.
- PEACH TRIAL: Precision medicine and adoptive cellular therapy
- This phase I study will evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy.
- Study of DSP-0390 in patients with recurrent high-grade glioma
-
- This phase I study will evaluate the safety and efficacy of the investigational treatment DSP-0390 in patients with recurrent high-grade glioma.
-
- The purpose of this early phase I study is to establish the safety and tolerability of simultaneous infusions of 5-Azacytidine and trastuzumab into the fourth ventricle of the brain or resection cavity in patients with recurrent posterior fossa ependymoma and to assess the antitumor activity of simultaneous infusions of 5-Azacytidine and trastuzumab into the fourth ventricle of the brain or resection cavity in patients based upon imaging studies and lumbar cerebrospinal fluid (CSF) cytology.
- A study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma
- This is a phase II therapeutic study that will assess the effects of combining the drug BPM31510 with standard of care treatments for subjects with newly diagnosed glioblastoma.
- 177Lu-DTPA-omburtamab radioimmunotherapy for recurrent or refractory medulloblastoma
- Children and adolescents diagnosed with medulloblastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab in this phase I/II trial.
- Testing the addition of the immunotherapy drugs tocilizumab and atezolizumab to radiation therapy for recurrent glioblastoma
- This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment (recurrent).
*For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder at trials.braintumor.org, where you can search potential opportunities for enrollment based on criteria specific to you.
**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing patientnavigator@braintumor.org. Our patient navigator, Mary Lovely, PhD, RN, CNRN, has more than 30 years of experience working closely with brain tumor patients and families as a neurological nurse, clinical nurse specialist, and research nurse. Learn more here.